Want to see NNVC full AI Analyst Report?
NNVC Stock Chart & Stats
$1.28
$0.06(4.05%)
At close: 4:00 PM EDT
$1.28
$0.06(4.05%)
Day’s Range― - ―
52-Week Range$0.85 - $2.23
Previous Close$1.56
Volume474.58K
Average Volume (3M)513.71K
Market Cap
$35.73M
Enterprise Value$23.30M
Total Cash (Recent Filing)$2.79M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Nov 23, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding25,525,000
10 Day Avg. Volume203,414
30 Day Avg. Volume513,714
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)3.21
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap0.65
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-89.84
Enterprise Value/Ebitda-3.02
Forecast
1Y Price Target
$6.00Price Target Upside368.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.41
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Platform Breadth And Pediatric PotentialNV-387’s strong juvenile-animal safety results expand the potential development scope into pediatric indications and support dosing flexibility. If translated clinically, this could broaden the platform’s addressable antiviral opportunities beyond adult treatment.
Clinical Development AdvancementProgress into Phase IIA Ebola dosing and a defined gate toward randomized Phase IIB represents meaningful clinical execution. Advancement across staged trials can generate more informative human safety and efficacy evidence for NV-387 over the next several quarters.
Low Financial LeverageEffectively zero debt and near-zero debt-to-equity reduce refinancing and interest-rate burdens. This gives management greater flexibility to direct available capital toward research and clinical programs, although it does not remove the need for financing.
Bears Say
Pre-revenue Loss ProfileZero reported revenue alongside persistent operating and net losses shows the pipeline has not yet produced commercial income. Continued pre-revenue development leaves results dependent on future clinical progress and potential product approval rather than established sales.
Persistent Cash BurnNegative operating and free cash flow in every year shown indicates ongoing cash burn rather than self-funded operations. Reliance on financing to fund activity can constrain strategic flexibility and expose the company to recurring capital-raising needs.
Declining And Uncertain Equity BaseDeclining stockholders’ equity through 2025 is consistent with cumulative losses and cash burn, while sharply higher 2026 equity and assets appear inconsistent with prior scale. This combination increases uncertainty around capital strength and reported earnings trends.
NanoViricides News
NNVC FAQ
What was NanoViricides’s price range in the past 12 months?
NanoViricides lowest stock price was $0.85 and its highest was $2.23 in the past 12 months.
What is NanoViricides’s market cap?
NanoViricides’s market cap is $35.73M.
When is NanoViricides’s upcoming earnings report date?
NanoViricides’s upcoming earnings report date is Nov 23, 2026 which is in 28 days.
How were NanoViricides’s earnings last quarter?
NanoViricides released its earnings results on Nov 24, 2025. The company reported -$0.135 earnings per share for the quarter, beating the consensus estimate of -$0.18 by $0.045.
Is NanoViricides overvalued?
According to Wall Street analysts NanoViricides’s price is currently Undervalued.
Does NanoViricides pay dividends?
NanoViricides does not currently pay dividends.
What is NanoViricides’s EPS estimate?
NanoViricides’s EPS estimate is -0.1.
How many shares outstanding does NanoViricides have?
NanoViricides has 25,525,000 shares outstanding.
What happened to NanoViricides’s price movement after its last earnings report?
NanoViricides reported an EPS of -$0.135 in its last earnings report, beating expectations of -$0.18. Following the earnings report the stock price went down -2.362%.
Which hedge fund is a major shareholder of NanoViricides?
Currently, no hedge funds are holding shares in NNVC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NanoViricides Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (368.75% Upside)
$6.00 (368.75% Upside)
Crowd Wisdom
Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 2.4%
Last 30 Days ▲ 2.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-2.16%
12-Months-Change
Fundamentals
Return on Equity
-91.11%
Trailing 12-Months
Asset Growth
11.89%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
NanoViricides
NanoViricides, Inc. operates as a nano-biopharmaceutical entity, specializing in the research, development, and market introduction of pharmaceutical solutions to combat viral infections. The company's robust product pipeline includes a Human Coronavirus Program, specifically engineered to tackle both COVID-19 and various seasonal coronaviruses. For herpes-related conditions, it offers HerpeCide in multiple forms: dermal topical and eye drops to treat ailments such as shingles, postherpetic neuralgia (PHN), chickenpox, recurrent herpes labialis, genital herpes, and ocular herpes keratitis. An intraocular injectable version of HerpeCide is also under development for viral acute retinal necrosis. Another significant therapeutic candidate is FluCide, a broad-spectrum anti-influenza nanoviricide, designed for both hospitalized patients via injection and outpatients through an oral formulation. NanoViricides also develops specialized nanoviricide eye drops for viral diseases affecting the external eye, DengueCide for various strains of Dengue viruses, and HIVCide, an anti-HIV nanoviricide specifically engineered to resist viral escape. Furthermore, the company is actively advancing additional nanoviricide drug projects targeting a diverse range of viruses and indications, alongside expanding its HerpeCide program to encompass a broader spectrum of herpes viruses and associated conditions. NanoViricides, Inc. was established in 2005 and maintains its corporate headquarters in Shelton, Connecticut.
NNVC Stock 12 Month Forecast
Average Price Target
$6.00
▲(368.75% Upside)
Technical Analysis
Ownership Overview
―
Insiders
2.69% Mutual Funds
0.61% Other Institutional Investors
93.03% Public Companies and
Individual Investors